Cargando…
Funder priority for vaccines: Implications of a weak Lockean claim
The development of some COVID‐19 vaccines by private companies like Moderna and Sanofi‐GSK has been substantially funded by various governments. While the Sanofi CEO has previously suggested that countries that fund this development ought to be given some priority, this suggestion has not been taken...
Autores principales: | Muralidharan, Anantharaman, Schaefer, G. Owen, Johnson, Tess, Savulescu, Julian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9539059/ https://www.ncbi.nlm.nih.gov/pubmed/35984666 http://dx.doi.org/10.1111/bioe.13075 |
Ejemplares similares
-
Queue questions: Ethics of COVID‐19 vaccine prioritization
por: Giubilini, Alberto, et al.
Publicado: (2021) -
Stopping exploitation: Properly remunerating healthcare workers for risk in the COVID‐19 pandemic
por: Giubilini, Alberto, et al.
Publicado: (2021) -
Vaccination status and intensive care unit triage: Is it fair to give unvaccinated Covid‐19 patients equal priority?
por: Shaw, David
Publicado: (2022) -
A trade‐off: Antimicrobial resistance and COVID‐19
por: Johnson, Tess
Publicado: (2021) -
Clinical and neurophysiological characterization of muscular weakness in severe COVID-19
por: Bax, Francesco, et al.
Publicado: (2021)